Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. Véniant MM, et al. Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5. Nat Metab. 2024. PMID: 38316982 Free PMC article. Clinical Trial.
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
Lu SC, Chen M, Atangan L, Killion EA, Komorowski R, Cheng Y, Netirojjanakul C, Falsey JR, Stolina M, Dwyer D, Hale C, Stanislaus S, Hager T, Thomas VA, Harrold JM, Lloyd DJ, Véniant MM. Lu SC, et al. Among authors: veniant mm. Cell Rep Med. 2021 Apr 30;2(5):100263. doi: 10.1016/j.xcrm.2021.100263. eCollection 2021 May 18. Cell Rep Med. 2021. PMID: 34095876 Free PMC article.
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, Véniant MM, Lloyd DJ. Killion EA, et al. Among authors: veniant mm. Sci Transl Med. 2018 Dec 19;10(472):eaat3392. doi: 10.1126/scitranslmed.aat3392. Sci Transl Med. 2018. PMID: 30567927
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, Busby J, Hecht R, Li YS, Li Y, Lindberg R, Véniant MM. Xu J, et al. Among authors: veniant mm. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1105-14. doi: 10.1152/ajpendo.00348.2009. Epub 2009 Aug 25. Am J Physiol Endocrinol Metab. 2009. PMID: 19706786 Free article.
Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G Jr, Graham M, Yan H, Wang P, Moore S, Meng T, Lindberg RA, Véniant MM. Gu W, et al. Among authors: veniant mm. Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E624-32. doi: 10.1152/ajpendo.00102.2010. Epub 2010 Jul 20. Am J Physiol Endocrinol Metab. 2010. PMID: 20647556 Free article.
80 results